DCGI’s green signal to Mylan’s launch of Avonza in India

The new drug by Mylan offers an innovative, reduced-dose alternative first-line regimen for people being treated for HIV/AIDS in India


New Delhi: The Mylan Pharmaceuticals has received marketing authorization from the Drug Controller General of India (DCGI) for its antiretroviral (ARV) drug Avonza (TLE400).

Avonza is a fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg, recommended by the World Health Organization (WHO) as an alternative first-line regimen for people being treated for HIV/AIDS.

Commenting on the launch, Mylan President Rajiv Malik mentioned, “Developing Avonza and bringing it to patients with HIV in India is a continuation of our strong and sustained commitment to expanding access to affordable, high-quality ARVs. Avonza will be available to patients at a cost that is lower than that of other current first-line ARVs. What’s more, Mylan is the first to offer this combination in India, making it another example of the innovative spirit that runs throughout our company to adapt our medicines, accelerate access and improve treatment outcomes.”

WHO recommended antiretroviral, Avonza is expected to help in expanding access to HIV-AIDS patients in India at a lower cost.

In April 2017, the Health Ministry in India launched the Test and Treat Policy for HIV; anyone testing positive for HIV will get antiretroviral therapy irrespective of CD4 count or clinical stage.


Mylan says that its product, Avonza also is another step the company is taking to help India meet its Sustainable Development Goal of ending AIDS by 2030.

Globally, Mylan supplies life-saving ARVs to nearly 50% of patients being treated for HIV/AIDS in more than 100 developing countries. The company’s comprehensive ARV portfolio includes 14 active pharmaceutical ingredients and 50 finished dosage forms in first-line, second-line and pediatric formulations.

Mylan, a global pharmaceutical company, offers a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in more than 165 countries and territories.